Gender and menopause impact severity of fibrosis among patients with nonalcoholic steatohepatitis
Ju Dong Yang(Mayo Clinic), Ayako Suzuki(Duke Medical Center), Anna Mae Diehl(Duke Medical Center), Manal F. Abdelmalek(Mayo Clinic), Cynthia D. Guy(Duke University Health System), Herbert Pang(Duke University), Alastair D. Smith(Duke Medical Center)
Cited by 374
Related Papers
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
|New England Journal of Medicine|2010|3.3k
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Hepatology|2023|2.9k
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Journal of Hepatology|2023|2.7k
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
|The Lancet|2014|2.2k
Sex and gender: modifiers of health, disease, and medicine
|The Lancet|2020|2k